We found a match
Your institution may have access to this item. Find your institution then sign in to continue.
- Title
One year outcomes with abciximab vs. placebo during percutaneous coronary intervention after pre-treatment with clopidogrel<sup>†</sup>.
- Authors
Schömig, Albert; Schmitt, Claus; Dibra, Alban; Mehilli, Julinda; Volmer, Christian; Schühlen, Helmut; Dirschinger, Josef; Dotzer, Franz; ten Berg, Jurriën M.; Neumann, Franz-Josef; Berger, Peter B.; Kastrati, Adnan
- Abstract
Aims In the Intracoronary Stenting and Antithrombotic Regimen-Rapid Early Action for Coronary Treatment Trial, the use of abciximab in patients undergoing percutaneous coronary intervention (PCI) after pretreatment with 600 mg clopidogrel for >2 h was associated with no clinically measurable benefit at 30 days. We assessed whether there was any clinical benefit from abciximab at 1 year follow-up.
- Publication
European Heart Journal, 2005, Vol 26, Issue 14, p1379
- ISSN
0195-668X
- Publication type
Article
- DOI
10.1093/eurheartj/ehi174